MedTrace Logo

Prognostic Value of BNP in MCS - a 25 Year Follow up Study

NCT04377854 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-05-05

No results posted yet for this study

Summary

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.

Patients will be followed up for 25 years after inclusion.

Conditions

  • Heart Failure
  • Left Ventricular Assist Device
  • Prognosis
  • Durable Mechanical Support Device

Interventions

OTHER

Observation. No intervention per se.

Observation. No intervention (no collection of blood).

OTHER

2) Observation and collection and of blood sample

All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2045-08-01
Completion
2045-08-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377854 on ClinicalTrials.gov